Advanz Pharma Launches Generic Lanreotide in Germany

Specialty pharmaceutical company, Advanz Pharma, has launched a generic version of lanreotide, MYTOLAC, in Germany for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumors and symptoms associated with neuroendocrine tumors.

“Until now, prescriber choice has been limited. The launch of a generic alternative means we are able to improve access and choice while helping to drive down costs,” said David Johnson, global director, Commercial Excellence, Advanz Pharma, in a July 21, 2021 press release.

“It is through our successful partnerships with regulators, manufacturers, and distributors across the region that [this] news has been made possible. We’re proud to announce the launch of this medicine in Germany […] and look forward to expanding this to other countries across Europe in the near future,” added Paul Burden, chief commercial officer, Strategic Business Unit, Advanz Pharma, in the press release. “This launch is the first of what we hope will be many, as we continue to expand into the complex and value-added medicines space, to the benefit of healthcare professionals and patients in Europe.”

Source: Advanz Pharma